SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 44,550
+700 (1.60%)
At close: Apr 16, 2026
SK bioscience Revenue
In the year 2025, SK bioscience had annual revenue of 651.37B KRW with 143.46% growth. SK bioscience had revenue of 184.19B in the quarter ending December 31, 2025, with 17.43% growth.
Revenue
651.37B
Revenue Growth
+143.46%
P/S Ratio
5.38
Revenue / Employee
710.33M
Employees
917
Market Cap
3.50T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 651.37B | 383.82B | 143.46% |
| Dec 31, 2024 | 267.55B | -101.96B | -27.59% |
| Dec 31, 2023 | 369.51B | -87.22B | -19.10% |
| Dec 31, 2022 | 456.73B | -472.28B | -50.84% |
| Dec 31, 2021 | 929.00B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.27T |
| SK Biopharmaceuticals | 706.74B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| LigaChem Biosciences | 141.55B |
| HLB Co., Ltd. | 84.17B |
| OliX Pharmaceuticals | 14.67B |
| Voronoi | 7.51B |